In Vitro Evaluation of Nonnucleoside Reverse Transcriptase Inhibitors UC-781 and TMC120-R147681 as Human Immunodeficiency Virus Microbicides

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 337-339

  Van Herrewege, Yven ^a   Michiels, Jo ^a   Van Roey, Jens ^b   Fransen, Katrien ^a   Kestens, Luc ^a   Balzarini, Jan ^c   Lewi, Paul ^d   Vanham, Guido ^a   Janssen, Paul ^d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Tibotec Virco NV ^*  (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d Center for Molecular Design   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TMC120 R147681;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANILIDES; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL-FREE SYSTEM; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FURANS; HIV INFECTIONS; HIV-1; HUMANS; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0347992022     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.337-339.2004     Document Type: Article

References (22)

1. Balzarini, J., E. De Clercq, A. Carbonez, V. Burt, and J. P. Kleim. 2000. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Res. Hum. Retrovir. 16:517-528.
2. Balzarini, J., L. Naesens, E. Verbeken, M. Laga, L. Van Damme, M. Parniak, L. Van Mellaert, J. Anne, and E. De Clercq. 1998. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 12:1129-1138.
3. Balzarini, J., M. J. Pérez-Pérez, A. San Felix, M. J. Camarasa, I. C. Bathurst, P. J. Barr, and E. De Clercq. 1992. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′ -bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″ -(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T). J. Biol. Chem. 267:11831-11838.
4. Borkow, G., J. Barnard, T. M. Nguyen, A. Belmonte, M. A. Wainberg, and M. A. Parniak. 1997. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71: 3023-3030.
5. Borkow, G., H. Salomon, M. A. Wainberg, and M. A. Parniak. 2002. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res. Hum. Retrovir. 18:711-714.
6. Buckheit, R. W., Jr., M. Hollingshead, S. Stinson, V. Fliakas-Boltz, L. A. Pallansch, J. Roberson, W. Decker, C. Elder, S. Borgel, C. Bonomi, R. Shores, T. Siford, L. Malspeis, and J. P. Bader. 1997. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res. Hum. Retrovir. 13:789-796.
7. Christopherson, C., Y. Kidane, B. Conway, J. Krowka, H. Sheppard, and S. Kwok. 2000. PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J. Clin. Microbiol. 38:630-634.
8. Di Fabio, S., J. Van Roey, G. Giannini, G. van den Mooter, M. Spada, A. Binelli, M. F. Pirillo, E. Germinario, F. Belardelli, M. P. de Bethune, and S. Vella. 2003. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17:1597-1604.
9. Elias, C. J., and L. L. Heise. 1994. Challenges for the development of female-controlled vaginal microbicides. AIDS 8:1-9.
10. Feldblum, P. J., C. S. Morrison, R. E. Roddy, and W. Cates, Jr. 1995. The effectiveness of barrier methods of contraception in preventing the spread of HIV. AIDS 9(Suppl. A):S85-S93.
11. Hart, C. E., J. L. Lennox, M. Pratt-Palmore, T. C. Wright, R. F. Schinazi, T. Evans-Strickfaden, T. J. Bush, C. Schnell, L. J. Conley, K. A. Clancy, and T. V. Ellerbrock. 1999. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J. Infect. Dis. 179:871-882.
12. Irwin, K., M. Scarlett, and R. Moseley. 1998. Observations from the CDC. The urgent need for new HIV/STD prevention options for women. J. Women's Health 7:1081-1086.
13. Ludovici, D. W., B. L. De Corte, M. J. Kukla, H. Ye, C. Y. Ho, M. A. Lichtenstein, R. W. Kavash, K. Andries, M. P. de Bethune, H. Azijn, R. Pauwels, P. J. Lewi, J. Heeres, L. M. Koymans, M. R. de Jonge, K. J. Van Aken, F. F. Daeyaert, K. Das, E. Arnold, and P. A. Janssen. 2001. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 11:2235-2239.
14. Milman, G., and O. Sharma. 1994. Mechanisms of HIV/SIV mucosal transmission. AIDS Res. Hum. Retrovir. 10:1305-1312.
15. Short, R. V. 1994. Contraceptives of the future in the light of HIV infection. Aust. N. Z. J. Obstet. Gynaecol. 34:330-332.
16. Spira, A. I., P. A. Marx, B. K. Patterson, J. Mahoney, R. A. Koup, S. M. Wolinsky, and D. D. Ho. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183:215-225.
17. Stafford, M. K., H. Ward, A. Flanagan, I. J. Rosenstein, D. Taylor-Robinson, J. R. Smith, J. Weber, and V. S. Kitchen. 1998. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:327-331.
18. Stein, Z. A. 1990. HIV prevention: the need for methods women can use. Am. J. Public Health 80:460-462.
19. Turpin, J. A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11:1077-1097.
20. Van Herrewege, Y., L. Penne, C. Vereecken, K. Fransen, G. van der Groen, L. Kestens, J. Balzarini, and G. Vanham. 2002. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. AIDS Res. Hum. Retrovir. 18:1091-1102.
21. Vernazza, P. L., J. J. Eron, S. A. Fiscus, and M. S. Cohen. 1999. Sexual transmission of HIV: infectiousness and prevention. AIDS 13:155-166.
22. Zhang, H., G. Dornadula, M. Beumont, L. Livornese, Jr., B. Van Uitert, K. Henning, and R. J. Pomerantz. 1998. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339:1803-1809.